[
    [
        {
            "time": "2020-07-07",
            "original_text": "健帆生物：预计上半年净利润同比增长30%至50%",
            "features": {
                "keywords": [
                    "健帆生物",
                    "净利润",
                    "同比增长",
                    "业绩预告"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物：预计上半年净利润同比增长30%至50%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-07-07",
            "original_text": "健帆生物(300529.SZ)：上半年净利预增30%-50%",
            "features": {
                "keywords": [
                    "健帆生物",
                    "净利预增",
                    "业绩增长"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529.SZ)：上半年净利预增30%-50%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-07-07",
            "original_text": "健帆生物(300529)：业绩延续高增长，全面业绩有保障【2020年中报业绩预告点评|西南医药杜向阳团队】",
            "features": {
                "keywords": [
                    "健帆生物",
                    "业绩延续高增长",
                    "全面业绩有保障",
                    "中报业绩预告"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物(300529)：业绩延续高增长，全面业绩有保障【2020年中报业绩预告点评|西南医药杜向阳团队】",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]